ArticleOpen heart2025
Long-term prognostic impact of in-hospital serum albumin concentration changes in patients hospitalised for heart failure.
Article in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined Prognostic Value of the PROFUND Index and Serum Albumin for One-Year Mortality in Elderly Patients with Acute Heart Failure.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalnutrition influences prognosis in patients with heart failure, but current nutritional evaluation methods are excessively complex for routine clinical use. The role of the serum albumin concentration, a widely used surrogate marker, in acute heart failure remains unclear. We assessed whether changes in serum albumin during heart failure hospitalisation can serve as a prognostic marker.
methodsAmong 14 847 patients in a nationwide heart failure registry in 2013, 5836 eligible patients (mean age: 77.7 years, 51.2% men) were categorised into two groups: the albumin-increase group (n=2048) and the no-albumin-increase group (n=3788). The incidences of primary (all-cause mortality) and secondary (a composite of cardiovascular death and rehospitalisation for worsening heart failure) outcomes were compared between the groups. The prognostic impact of serum albumin changes was also evaluated.
resultsThe median follow-up period was 1545 days (95% CI 1535 to 1557 days). Event-free survival rates for clinical outcomes were higher in the albumin-increase group than in the no-albumin-increase group (primary outcome: 54.5% vs 45.4%, 95% CI 51.4% to 57.6% vs 42.9% to 47.8%, p<0.005; secondary outcome: 40.5% vs 36.9%, 95% CI 36.4% to 44% vs 34.1% to 39.6%, p<0.005). A generalised additive model revealed a linear relationship between serum albumin changes and prognosis; declines had a stronger negative effect than the positive impact of increases, but the change rate better reflected the relationship with prognosis. Survival classification and regression tree analysis indicated that a 25% decrease in the serum albumin concentration identified the most vulnerable population; even a 3% decrease was associated with worse outcomes.
conclusionsSerum albumin changes during hospitalisation can predict prognosis in patients with heart failure, indicating potential as a target for interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.